Combination Therapy for Solid Tumour Cancer
AssigneeUniversity College Cork, National University of Ireland, Cork
InventorsMark Tangney, Panos Lehouritis
Life of this patent
Estimating the term…
Abstract
A combination comprising an effective dose of a chemotherapeutic-activating wild-type bacterium and an effective dose of a chemotherapeutic agent that is responsive to the chemotherapeutic activating wild-type bacterium, for use in a method of preventing or treating a solid tumour cancer in a mammal.
Claims17
A method of treating a solid tumour cancer in a mammal comprising the step of administering to the mammal an effective dose of a chemotherapeutic-activating wild-type bacterium and an effective dose of a chemotherapeutic agent that is responsive to the chemotherapeutic activating wild-type bacterium.
d according to claim 1 in which the chemotherapeutic-activating wild-type bacterium is selected from E. coli, Listeria, Lactobacillus, Bifidobacteria, and Lactococcus, and in which the chemotherapeutic agent is selected from Tegafur, Fludarabine de phosphate, 5-fluorcytosine, 6-mercaptopurine-2′-deoxyriboside, CB1954 and AQ4N.
A composition comprising a chemotherapeutic-activating wild-type bacterium and a chemotherapeutic agent that is responsive to the chemotherapeutic activating wild-type bacterium.
A method of treating a solid tumour cancer in a mammal comprising the steps of administering to the mammal an effective dose of a wild-type bacterium susceptible chemotherapeutic agent and an effective dose of an anti-bacterial agent effective against the wild-type bacterium.
Dependencies are inferred from the claim text.